The First New Ischemic Stroke Treatment in 25 years by DiaMedica Therapeutics
Rick Pauls, President and CEO of DiaMedica Therapeutics, a clinical-stage biopharma committed to improving the lives of people suffering serious diseases, with initial focus on acute ischemic stroke (AIS) and chronic kidney disease (CKD) joins eHealth Radio and the Health News Channel.
Listen to host Eric Dye & guest Rick Pauls discuss the following:
DiaMedica is currently enrolling for a phase 3 clinical trial for an ischemic stroke treatment that is able to be administered to patients within 24 hours of the onset of symptoms. Compared to the current treatment of over 25 years with only a 4-hour window, can you enlighten listeners on how this science is disrupting the trajectory of stroke therapy?
DiaMedica's lead candidate, DM199, is a synthetic form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. A form of human KLK1, isolated from human urine, is approved in China for subacute treatment of AIS. As of now, in the U.S., only an IV injection of recombinant tissue plasminogen activator (TPA) is the standard treatment for ischemic stroke. Can you expand on how DiaMedica's recombinant protein replacement therapy works?
What is unique about the company's drug and trial design is that you plan to assess two separate clinically meaningful endpoints, stroke recoveries and prevention of ischemic stroke recurrence, across the same study population. What are the clinical benefits of this structure?
DiaMedica is currently enrolling at ten clinical trial sites across the country. Why is it advantageous for listeners to know which local hospital is participating in the first new ischemic stroke treatment in 25 years?
The FDA granted Fast Track Designation to DM199 for the treatment of AIS in September 2021. Fast Track is a process intended to facilitate the development and expedite the review of investigational drugs for the treatment of serious or life-threatening conditions where there is a significant unmet medical need. What are the next steps here, and what timeline are we looking at for phase 3 data?
Rick Pauls was appointed President and Chief Executive Officer of DiaMedica Therapeutics in July 2009. Mr. Pauls has served as a member of DiaMedica’s board of directors since April 2005 and as the Chairman of the Board from April 2008 to July 2014. Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, an early-stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999, Mr. Pauls worked for General Motors Acceptance Corporation specializing in asset-backed securitization and structured finance. Additionally, Mr. Pauls has served on the board of directors of several public and private companies. Mr. Pauls received his B.A. in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.